Biography

Pharmaceutical scientist with over 25 years of experience in anti-tuberculosis drug development at Dong-A ST. Holds an M.S. in Organic Chemistry and a Ph.D. in Pharmacy. Specialized in both novel drug discovery and generic drug development. Successfully collaborated with the World Health Organization (WHO) to develop and globally supply generic clofazimine, cycloserine, and terizidone. Currently serves as the project leader for DA-7801, a new anti-TB drug candidate. Skilled in preclinical and clinical development, regulatory strategy, and global health partnerships. Demonstrates a strong track record in delivering innovative solutions for global TB control and contributing to public health impact.

Expertise

TB Diagnostics
Public Health

Key Impacts

DA-7801: Cost-effective anti-TB drug with strong efficacy and low toxicity

DA-7801 meets key preclinical requirements for anti-TB drug development and is poised to enter clinical trials. It has demonstrated broad-spectrum activity from drug-susceptible (DS) to multidrug-resistant (MDR) TB. A combination regimen with bedaquiline is also under investigation to shorten MDR treatment duration. With its simple synthesis and low-cost scalability, DA-7801 holds promise for enhancing global TB treatment accessibility.

Source: Conference 2024